Skip to main content

Table 2 Haemoglobin response and clinical parameters

From: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients

Clinical paramaters Response to EPO, N(%) Chi square
Non Response Response P value
Response to Glivec    
SD + PR 9(56.3%) 18(100%) 0.02
PD 7(44%) 0(0%)  
Male 9(56.3%) 9(50%) 0.7
Female 7(44%) 9(50%)  
Liver metastases    
No 1(6.3%) 5(28%) 0.2
Yes 15(94%) 13(72%)  
Lung metastases    
No 14(875%) 16(89%) 1.0
Yes 2(12.5%) 2(11%)  
Peritoneal metastases    
No 3(19%) 6(33.5%) 0.44
Yes 13(81.5%) 12(66.5%)  
Imatinib dose    
400 mg/d 9(56.3%) 16(89%) 0.05
800 mg/d 7(44%) 2(11%)  
Age    
≥ 60 years 8(50%) 9(50%) 1.0
< 60 years 8(50%) 9(50%)  
  1. ° Ficher exact test.